Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Untargeted Serum Metabolomics Reveals Differential Signatures in Gallstone-Associated and Gallstone-Free Gallbladder Cancer

ABSTRACT:

Gallbladder cancer (GBC) is an aggressive malignancy often associated with gallstones (GBCGS), a condition distinct from gallstone disease (GSD). Both GBC and GBCGS are rare, with unclear pathogenesis and no established biomarker-based solutions. This pilot study aimed to identify distinct metabolic signatures in GBC and GBCGS for early diagnosis and stratification of high-risk GSD patients. A comparative untargeted serum metabolomic profiling was performed across three patient groups: GBC (n1=9), GBCGS (n2=11), and GSD (n3=10). A total of 35,385 mass-features in both positive and negative ionization modes with MS/MS characteristics were detected and annotated into 736 biochemicals.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase

PROVIDER: MTBLS12514 | MetaboLights | 2025-12-22

REPOSITORIES: MetaboLights

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	GBC1.abf	Other
	GBC10.abf	Other
	GBC2.abf	Other
	GBC3.abf	Other
	GBC4.abf	Other

Items per page:

1 - 5 of 36

Similar Datasets

The gene expression profiles of gallbladder cancer

Project description:Gallbladder cancer is a rare but highly malignant cancer. We performed the transcriptional profile sequencing to figure out the potential mechanisms, which might significantly affect gallbladder cancer progression.

2019-11-01 | GSE139682 | GEO

CEACAM6 orchestrates gallbladder cancer aggressiveness through molecular interplay with Integrin and PRKCD [GB-d1]

Project description:Gallbladder cancer (GBC) comprises the most common biliary tract cancer (BTC). However, GBC is a rare disease often manifesting as aggressive malignancy due to its late diagnosis and resistance to chemotherapy. The identification of molecular drivers of GBC and identification of targeted therapies is still urgently needed. This study combined proteomic analysis of GBC patient samples, functional and molecular characterization of potential oncogenes, and identification of potential therapy strategy for GBC. We identified Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) as one of the strongest and most significant upregulated proteins in GBC samples. Functional analysis and in vivo mouse models revealed that CEACAM6 supported the initial steps of cancer metastasis by decreasing cell adhesion while promoting migration and invasion of GBC cells. BirA-BioID followed by mass-spectrometry revealed Integrin Beta-1 (ITGB1) and Protein Kinase C Delta (PRKCD) as direct molecular and functional partners of CEACAM6 in supporting GBC cell migration through regulation of ERK and AKT downstream target genes MMP13, MMP14, and OCLN. Conversely, CEACAM6 knockdown abolished GBC aggressiveness, and treatment using AKT inhibitor Capivasertib and ERK inhibitor Ulixertinib counter-acted the CEACAM6-induced migration.These findings demonstrate that CEACAM6 is crucial for gallbladder oncogenesis through ERK and AKT signaling, providing insights into the design of therapeutic strategies for GBC.

2024-10-30 | GSE243305 | GEO

CEACAM6 orchestrates gallbladder cancer aggressiveness through molecular interplay with Integrin and PRKCD [SNU308]

2024-10-30 | GSE243304 | GEO

The gene expression profile of methotrexate-resistant JAR cells

Project description:Choriocarcinoma is a rare and aggressive malignancy. Although multi-agent chemotherapy is the standard treatment, resistance to anticancer agents remains a significant clinical challenge. In this study, we investigated the gene expression profile of choriocarcinoma cells with acquired resistance to methotrexate (MTX) using mRNA sequencing.

2026-02-21 | GSE300458 | GEO

Characterisation of a cell-free myxoid liposarcoma patient-derived xenograft scaffold model

Project description:Myxoid liposarcoma (MLS) is the second most common type of liposarcoma, and today few model systems to study the disease exists. To be able to model the disease in vitro, cell-free scaffolds from MLS patient-derived xenograft (PDX) models were generated. The MLS scaffolds were then used as a 3D growth platform for MLS cell lines to study the cancer microenvironments impact on cellular heterogeneity using RNA sequencing. Key components in the microenvironment have also been shown to influence the fraction of cellular subpopulations, such as cancer stem cells and migratory cells but also to promote aggressive features of cancers. Therefore, to better understand and characterize these scaffolds, protein analyses were performed and links between scaffold compositions and the induced gene expression profiles of the cells grown therein could be made. This model system provides a better insight to the composition of the cell-free cancer microenvironment in a rare disease, which can lead to identification of novel malignancy inducing properties in MLS.

2024-05-08 | PXD023792 | Pride

Methylation of a gestational choriocarcinoma

Project description:Gestational choriocarcinoma arises from the cells of conception and is usually characterized as a fast growing, invasive and aggressive malignancy. The overall incidence is approximately 1 case per 50,000 pregnancies and aside from increasing maternal age does not appear to have any other risk factors. In contrast to most malignancies, gestational choriocarcinoma is frequently treated on a clinical diagnosis without a biopsy and therefore tumor samples of sufficient quantity to permit detailed genetic analysis are exceptionally rare. As a result, no previous whole genome sequencing or methylation studies have been reported for this rare diagnosis. With the aim of investigating the potential contribution of epigenetic changes to the pathogenesis of this rare malignancy, we have performed a methylation analysis from routine processed FFPE material in a case of intra-placental choriocarcinoma.

2019-08-21 | GSE125386 | GEO

Multi-omic profiling unveils molecular landscapes and heterogeneous tumor microenvironment in sinonasal squamous cell carcinoma [RPMI 2650 bulk ATAC-seq]

Project description:Sinonasal squamous cell carcinoma (SNSCC) is a rare and aggressive malignancy with limited treatment options. Here, we conduct a comprehensive multi-omic analysis, integrating bulk and single-cell transcriptomics, epigenomics, and DNA methylation profiling. Our study identifies distinct gene signatures, cellular compositions, and regulatory mechanisms that drive SNSCC pathogenesis. Epigenetic alterations reveal a regulatory landscape underlying transcriptional changes, and we characterize heterogeneous tumor cell populations with unique molecular profiles. Hypoxia-related cells emerge as key drivers of angiogenesis and disease progression. Notably, we uncover a critical interaction between hypoxic tumor cells and endothelial tip cells, mediated by factors such as adrenomedullin (ADM), highlighting a pivotal mechanism in tumor development. These findings provide valuable insights into the tumor microenvironment (TME) of SNSCC and suggest potential therapeutic targets to improve treatment strategies for this challenging malignancy.

2026-01-26 | GSE298564 | GEO

Multi-omic profiling unveils molecular landscapes and heterogeneous tumor microenvironment in sinonasal squamous cell carcinoma [RPMI2650 bulk RNA-seq]

2026-01-26 | GSE298563 | GEO

Multi-omic profiling unveils molecular landscapes and heterogeneous tumor microenvironment in sinonasal squamous cell carcinoma [Bulk RNA-seq]

2026-01-26 | GSE278145 | GEO

Multi-omic profiling unveils molecular landscapes and heterogeneous tumor microenvironment in sinonasal squamous cell carcinoma [DNA methylation]

2026-01-26 | GSE278138 | GEO